Home Newsfeeds Identiv Q4 Sales $29.00M Beat $27.87M Estimate

Identiv Q4 Sales $29.00M Beat $27.87M Estimate

Identiv (NASDAQ: INVE) reported quarterly sales of $29.00 million which beat the analyst consensus estimate of $27.87 million by 4.06 percent. This is a 1.70 percent increase over sales of $28.52 million the same period last year.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Identiv (NASDAQ:INVE) reported quarterly sales of $29.00 million which beat the analyst consensus estimate of $27.87 million by 4.06 percent. This is a 1.70 percent increase over sales of $28.52 million the same period last year.

Effective As Of January 17, Sizzle Acquisition Corp’s Board Had Resolved And Removed Nestor Nova From Position Of Its Chief Financial Officer

By Benzinga Newsdesk

January 18, 9:17 AM

Form 8 Filing

SZZL

FDA Approves AbbVie/Genmab’s Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients

By Vandana Singh

May 19, 1:59 PM

The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or

ABBV

Terreno Realty Corporation Sells Property In Compton, CA For $15.9M

By Benzinga Newsdesk

January 2, 10:15 AM

Terreno Realty Corporation (NYSE:TRNO), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, sold an industrial property located in Compton, California on December 27, 2023 for a

TRNO